KH6.F NewAmsterdam Pharma Company N.V.
- Market cap
- EUR 2.13B
- P/E
- -
- P/B
- 3.55x
- ROE
- -27.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is KH6.F undervalued?
Graham numberThe Graham number of NewAmsterdam Pharma Company N.V. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NewAmsterdam Pharma Company N.V. fundamental analysis
No fundamental analysis for NewAmsterdam Pharma Company N.V. yet.
NewAmsterdam Pharma Company N.V. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial fo…
Full company profileNewAmsterdam Pharma Company N.V. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
NewAmsterdam Pharma Company N.V. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 103M | 14.1M | 45.6M | 22.5M | 34.5M |
| Operating Income | -3.56M | -183M | -176M | -226M | -223M |
| EBITDA | -22.3M | -183M | -176M | -225M | -223M |
| Net Income | -22.6M | -177M | -242M | -204M | -173M |
| EPS | -0.28 | -2.15 | -2.24 | -1.78 | -1.45 |
| Balance Sheet | |||||
| Total Assets | 478M | 347M | 865M | 769M | 688M |
| Total Liabilities | 48.4M | 58.7M | 107M | 85.9M | 57.2M |
| Shareholders' Equity | 430M | 288M | 758M | 683M | 631M |
| Cash & Short-term Investments | 468M | 340M | 772M | 490M | 423M |
| Cash Flow | |||||
| Operating Cash Flow | 10.7M | -141M | -159M | -148M | -146M |
| Capital Expenditure | 221K | 24.0K | 672K | 246K | 393K |
| Free Cash Flow | 10.4M | -141M | -159M | -148M | -147M |
| Ratios | |||||
| ROE | -5.3% | -61.4% | -31.9% | -29.8% | -27.5% |
| ROA | -4.7% | -51.0% | -27.9% | -26.5% | -25.2% |
| Net Profit Margin | -22.0% | -1,255.8% | -530.3% | -905.7% | -501.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
NewAmsterdam Pharma Company N.V. dividends
NewAmsterdam Pharma Company N.V. has not paid dividends in the last 4 fiscal years.
Who owns NewAmsterdam Pharma Company N.V.
- Insiders 0.89%
- Institutions 99.11%
- Public & others 0.00%
- Shares outstanding 120M
- Free float 81.9M
NewAmsterdam Pharma Company N.V. company profile
- Company name
- NewAmsterdam Pharma Company N.V.
- Ticker
- KH6.F
- ISIN
- NL00150012L7
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 100
- Fiscal year end
- December
- Address
- Gooimeer 2-35, Naarden, Netherlands, 1411 DC
- Phone
- 31 35 206 2971
- Website
- newamsterdampharma.com
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
NewAmsterdam Pharma Company N.V. management
10- Dr. Michael Harvey Davidson FACC, Facp., M.D.CEO, President & Executive Director · born 1956
- Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D.Founder, Chief Scientific Officer, Member of Executive Board & Director · born 1954
- Mr. Mayur Amrat SomaiyaChief Financial Officer · born 1974
- Mr. Robert W. Gunning CPA, CGMAPrincipal Accounting Officer, VP & Controller · born 1971
- Mr. Matthew PhilippeExecutive VP & Head of Investor Relations
- Mr. Michael F. Marino Esq.Chief Legal Officer & Corporate Secretary · born 1976
- Mr. Chris DeluzioExecutive Vice President of Sales Enterprise Operations
- Ms. Maryellen McQuadeChief People Officer
- Ms. Juliette Audet M.B.A., M.Sc.Chief Strategy & Business Officer · born 1987
- Dr. Marc Ditmarsch M.D.Chief Development Officer · born 1967